Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03989986
Other study ID # 1727
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 1, 2020
Est. completion date December 31, 2024

Study information

Verified date April 2024
Source The Hospital for Sick Children
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The iPeer2Peer Sickle Cell Disease (SCD) study matches youth (12-18 years of age) with SCD to a mentor (trained young adult) who has learned to manage their SCD well, transitioned to adult care, and can support youth participants emotionally and socially. Participants will be randomly assigned one of two groups, either (1) The intervention group: Study group participants are matched with a mentor for 15 weeks, and are expected to have up to ten calls with one another; (2) The control group: This study group will be on a 15 week waitlist to receive a mentor. This study will first assess the feasibility of conducting this research with youth with SCD. Also, this study will assess the preliminary effectiveness of peer mentorship by comparing various health outcomes of the two study groups post-intervention.


Description:

Sickle Cell Disease (SCD) is a disease affecting red blood cells, where severe pain can develop due to blockage of red blood cells. This the most common genetic blood disease in North America, affecting mostly people of African descent. This type of pain can affect many aspects of one's life, and one's quality of life. Young people with SCD experience pain as they grow from childhood to adulthood, and experience daily chronic pain. There are many negative consequences of SCD, such as anxiety, depression, poor sleep, high stress, and limited social and physical activity. Peer support is a form of support that can provide someone with emotional, informational and social support. Peer support is a promising way of delivering emotional support, while helping someone learn how to cope and manage their disease. This is especially important for chronic diseases such as SCD, because young people will have to learn how to cope and manage their condition while growing up, and for the rest of their lives. A new way to provide face-to-face peer support is through the use of a virtual program using Skype via the Internet (to maintain face-to-face contact between mentors and mentees). In this program, a young adult (a mentor) with a chronic disease is matched with a younger person living with the same disease (a mentee) online, through Skype. The mentors are nominated by their healthcare teams, and have successfully transitioned to adult care. They are trained to talk to young people about their disease and can give them some advice on how to manage, and grow up with the condition. This program has been tested with other groups with Juvenile Idiopathic Arthritis and Chronic Pain. A mentor and a mentee are matched for 15 weeks and are encouraged to have up to ten Skype calls together. The investigators do not know how well this program will work with young people with SCD. Therefore, the investigators would like to test out this program to see if it is feasible to conduct the iPeer2Peer SCD program in the future as a larger study with the SCD population. Feasibility will be measured through the following: (1) recruitment and withdrawal rates; (2) rate of completion of weekly calls; (3) rate of completion of baseline measures; (4) estimates of intervention effects on health outcomes to inform the calculation of an appropriate sample size for the future definitive multi-centred randomized controlled trial (RCT) and (5) participants' perception regarding the acceptability of the SCD iP2P program and their level of engagement with the program (via a semi-structured interview). Descriptive statistics will be used to describe the sample characteristics at baseline. Rates of accrual, drop out, compliance, and missing data with 95% confidence intervals will be calculated.To inform sample size calculations and data analysis feasibility for a larger trial, data will be analyzed as in a larger study, and estimates of variance will be calculated. Secondary analysis will be conducted using an intent-to-treat approach. If assumptions for parametric statistics are met, linear regression models will be used to test intervention effects on pain impact, social support, self-efficacy, adherence and HRQL outcomes using an analysis of covariance approach with post-intervention measures compared between groups using baseline scores as covariates. The semi-structured individual (mentees) and focus group (mentors) interviews will determine (i) mentees' acceptability of and level of engagement in the iP2P program and (ii) mentors' likes and dislikes of program, improvement. This data, and subsequent analyses, will be used to refine the iP2P program prior to a full trial. A larger study will help to understand if peer support delivered by a mentor over Skype will help teenagers with SCD better manage their SCD, improve their health outcomes, and ultimately improve their quality of life living with SCD.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 28
Est. completion date December 31, 2024
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group 12 Years to 18 Years
Eligibility Inclusion Criteria: - Aged 12-18 years old - Diagnosed with SCD by a haematologist - Able to speak and read English - Access to Internet connection with computer capable of using free Skype software - Willing and able to complete online measures. Exclusion Criteria: - Significant cognitive impairments - Major co-morbid illnesses (medical or psychiatric conditions) likely to influence HRQoL assessment - Currently participating in other peer support or self-management interventions.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
iPeer2Peer Mentorship
Mentors and participants can have up to ten Skype calls over the course of 15 weeks.

Locations

Country Name City State
Canada Children's Hospital of Eastern Ontario (CHEO) Ottawa Ontario
Canada Jim Pattison Saskatoon Saskatchewan
Canada The Hospital for Sick Children Toronto Ontario
United States Connecticut Children's Medical Center Hartford Connecticut

Sponsors (4)

Lead Sponsor Collaborator
The Hospital for Sick Children Children's Hospital of Eastern Ontario, Connecticut Children's Medical Center, Royal University Hospital Foundation

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recruitment Rate The number of participants recruited for the study during the recruitment study period. 2 years
Primary Rates of completion of mentor-mentee calls Compliance defined as 100% when a participant completes 10 calls within 15 weeks with their mentor 15 weeks
Primary Withdrawal Rate Number of participants that withdraw from the study over the study period 2 years
Primary Acceptability of iPeer2Peer SCD intervention Participants' perception regarding the acceptability of the SCD iP2P program and their level of engagement with the program (via a semi-structured interview). 15 weeks
Secondary Sickle Cell Disease Pain Burden Interview- Youth 7-item questionnaire, measuring pain burden Baseline and 15 weeks after baseline completion.
Secondary Sickle Cell Disease Self-Efficacy Scale 9-item questionnaire, measuring self-efficacy Baseline and 15 weeks
Secondary PROMIS- Pediatric Peer Relationships 8a 8-item questionnaire, measuring social support from peers Baseline and 15 weeks
Secondary PROMIS depressive symptoms - 8a 8-item questionnaire, measuring depression Baseline and 15 weeks
Secondary PROMIS anxiety - 8a 8-item questionnaire, measuring anxiety Baseline and 15 weeks
Secondary PROMIS Pain Interference - 8a 8-item questionnaire, measuring consequences of pain on relevant aspects of person's life. Baseline and 15 weeks
Secondary PROMIS pain intensity - 1a 1-item questionnaire, measuring intensity of pain over the past week Baseline and 15 weeks
Secondary Transition-Q 14-item questionnaire, measuring self-management Baseline and 15 weeks
See also
  Status Clinical Trial Phase
Completed NCT02227472 - Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
Recruiting NCT06301893 - Uganda Sickle Surveillance Study (US-3)
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed NCT02522104 - Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) Phase 4
Recruiting NCT04688411 - An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease N/A
Terminated NCT03615924 - Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease Phase 3
Not yet recruiting NCT06300723 - Clinical Study of BRL-101 in Severe SCD N/A
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Completed NCT04134299 - To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease N/A
Completed NCT04917783 - Health Literacy - Neurocognitive Screening in Pediatric SCD N/A
Completed NCT02580565 - Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Completed NCT04388241 - Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD N/A
Recruiting NCT05431088 - A Phase 2/3 Study in Adult and Pediatric Participants With SCD Phase 2/Phase 3
Completed NCT01158794 - Genes Influencing Iron Overload State
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Withdrawn NCT02960503 - Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease Phase 1/Phase 2
Completed NCT02567682 - Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects Phase 1
Completed NCT02565082 - Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients N/A
Withdrawn NCT02630394 - A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease Phase 1